Skip to main content

MEDIFAST INC Value Stock - Dividend - Research Selection

Medifast inc

ISIN: US58470H1014 , WKN: 889384

Market price date:
Market price:  


Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Ratios
Key figures
Cash flow
P/C
 
P/FC
Balance sheet
ROI
ROE
Income statement
P/E
Div. Yield %
P/B
P/S


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



Description Data
Symbol
Market Capitalization USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internet


Description of the company

Medifast, Inc., through its subsidiaries, manufactures and distributes weight loss, weight management, healthy living products, and other consumable health and nutritional products in the United States and the Asia-Pacific. The company offers bars, bites, pretzels, puffs, cereal crunch, drinks, hearty choices, oatmeal, pancakes, pudding, soft serves, shakes, smoothies, soft bakes, and soups under the OPTAVIA, Optimal Health by Take Shape for Life, and Flavors of Home brands. It markets its products through point-of-sale transactions over ecommerce platform. The company was founded in 1980 and is based in Baltimore, Maryland.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov,


NEWS


OPTAVIA Survey Reveals 80% of Americans Lack Understanding of Metabolic Health Despite Its Major Impact to Overall Health and Wellbeing

2025-12-09
BALTIMORE, December 09, 2025--OPTAVIA, the science-backed, coach-guided lifestyle system, announced a new report "Metabolic Health in America: Awareness, Attitudes and Action." The report includes findings based on an online survey conducted by OPTAVIA with KRC Research among a nationally representative group of U.S. adults ages 18–75, recruited to match U.S. Census demographics*. The data highlights a pressing concern: 80% of American adults lack understanding of metabolic health, yet many are

Why Medifast (MED) Stock Is Up Today

2025-12-08
Shares of wellness company Medifast (NYSE:MED) jumped 3.6% in the afternoon session after reports highlighted a consensus analyst price target suggesting a potential upside of more than 51%. A survey of recent analyst ratings showed a consensus target price for Medifast at $16.50. This price level implied a potential gain of 51.31% for the stock from its trading price at the time of the report. The bullish outlook appeared to have resonated with investors.

Tempus AI Boosts Its Clinical AI Capabilities Through Strategic Moves

2025-12-05
TEM expands its clinical AI reach through regulatory wins, a new oncology partnership and a major digital-pathology acquisition.

3 Stocks Under $50 We’re Skeptical Of

2025-12-03
The $10-50 price range often includes mid-sized businesses with proven track records and plenty of growth runway ahead. They also usually carry less risk than penny stocks, though they’re not immune to volatility as many lack the scale advantages of their larger peers.

3 of Wall Street’s Favorite Stocks We Keep Off Our Radar

2025-12-01
Wall Street has set ambitious price targets for the stocks in this article. While this suggests attractive upside potential, it’s important to remain skeptical because analysts face institutional pressures that can sometimes lead to overly optimistic forecasts.

Hims & Hers Expands Care Scope as Digital Health Platforms Evolve

2025-11-25
HIMS expands into low testosterone and menopause care, with plans for longevity and global growth in 2026.

3 Small-Cap Stocks That Fall Short

2025-11-24
Investors looking for hidden gems should keep an eye on small-cap stocks because they’re frequently overlooked by Wall Street. Many opportunities exist in this part of the market, but it is also a high-risk, high-reward environment due to the lack of reliable analyst price targets.

3 Unprofitable Stocks That Fall Short

2025-11-21
Unprofitable companies face headwinds as they struggle to keep operating expenses under control. Some may be investing heavily, but the majority fail to convert spending into sustainable growth.

Medifast Scientific & Clinical Affairs Team Showcases New Research in Metabolic Health at ObesityWeek Conference

2025-11-13
BALTIMORE, November 13, 2025--Medifast, the health and wellness company known for its science-backed, coach-guided lifestyle system, continues to lead the charge in addressing the growing health crisis of metabolic dysfunction by unveiling new research findings during ObesityWeek. Hosted by The Obesity Society in Atlanta, Georgia November 4–7, 2025, the annual conference for obesity researchers and clinicians centers on the latest developments in evidence-based obesity science: cutting-edge basi

5 Insightful Analyst Questions From Medifast’s Q3 Earnings Call

2025-11-10
Medifast’s third quarter results met Wall Street’s revenue expectations, but the market responded negatively as sales continued to decline sharply year-over-year. Management attributed these results to ongoing headwinds in the weight loss industry—most notably, increased competition from GLP-1 medications and declines in the number of active earning coaches. CEO Dan Chard highlighted that the company’s evolving science-backed approach to metabolic health aims to differentiate Medifast in a chang